We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Clinigen Group Plc | LSE:CLIN | London | Ordinary Share | GB00B89J2419 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 925.00 | 924.50 | 925.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCLIN
Clinigen Group plc
21 July 2021
21 July 2021
Clinigen and ORPHELIA Pharma sign an exclusive agreement to supply Kigabeq(R) (vigabatrin)
Clinigen Group plc (AIM: CLIN, 'Clinigen'), the global pharmaceutical Products and Services company, and ORPHELIA Pharma, a pharmaceutical company specialised in orphan and paediatric medicines, announce that they have signed an exclusive agreement to manage the supply and distribution of Kigabeq(R) into unlicensed markets.
Kigabeq(R) was granted a European Paediatric Use Marketing Authorization (PUMA) in September 2018 and is currently approved for the treatment of infantile spasms (West Syndrome) and pharmaco-resistant focal-onset seizures (partial seizures).
Under the terms of the agreement, Clinigen will provide access to Kigabeq(R) 500 mg and 100 mg soluble tablets into markets where Kigabeq(R) is not commercially available. Clinigen will manage all elements of the supply including healthcare practitioner enquiry management, regulatory oversight, logistics and access management. The agreement currently covers all global territories except for USA, China, EU, UK and Bangladesh.
Sam Herbert, Chief Operating Officer and Head of Products Division, Clinigen, said: "We are pleased to be partnering with ORPHELIA Pharma and to be supplying Kigabeq(R) through our product lifecycle platform. This agreement will offer healthcare professionals another option to treat difficult-to-manage types of epilepsy. This is a great example of how Clinigen's lifecycle platform can help patients gain access to medicines which are not otherwise available."
Hugues Bienaymé, General Manager of ORPHELIA Pharma added :
" We are delighted to have entered into this collaboration with Clinigen. With this agreement, our ambition to make Kigabeq(R) available worldwide, will be fulfilled."
Healthcare professionals can obtain details about the products by calling the Clinigen customer service team at +44 (0) 1932 824100, emailing MedicineAccess@clinigengroup.com or going online at
www.clinigendirect.com .
Patients seeking medical information should contact their physician.
- Ends -
Contact details
Clinigen Group plc +44 (0) 1283 495010 Sam Herbert investors@clinigengroup.com Group Chief Operating Officer & Head of Products Division Consilium Strategic Communications Mary-Jane Elliott / Matthew Cole / Jessica Tel: +44 (0) 20 3709 Hodgson 5700 Clinigen@consilium-comms.com ORPHELIA Pharma Tel: +33 (0)1 42 77 Séverine MARTIN 08 18 orphelia@orphelia-pharma.eu
Notes to Editors
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global, specialist pharmaceutical services and products platform focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time. The Group operates from sites in North America, Europe, Africa and the Asia Pacific.
Clinigen has more than 1,000 employees across five continents in 16 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 34 of the top 50 pharmaceutical companies; interacting with over 5,000 hospitals across more than 115 countries.
For more information on Clinigen, please visit http://www.clinigen.com
About ORPHELIA Pharma
ORPHELIA Pharma is a biopharmaceutical company based in Paris and Lyon that develops and markets drugs for the treatment of paediatric and orphan diseases. Its mission is to provide patients with essential hospital products in the fields of epilepsy and oncology, with formulations that are suited to the paediatric population. ORPHELIA's first product, Kigabeq(R), which was approved during the latter part of 2018 for the treatment of West Syndrome in particular, has been launched in several European countries. Its second product, Ivozall(R), obtained a European marketing authorization at the end of 2019 for the treatment of acute lymphoblastic leukaemia. ORPHELIA Pharma also conducts research projects through academic and industrial partnerships.
For further information, please go to www.orphelia-pharma.eu
About Kigabeq(R)
Kigabeq is indicated in infants and children from 1 month to less than 7 years of age for:
Treatment in monotherapy of infantile spasms (West's syndrome).
Treatment in combination with other antiepileptic medicinal products for patients with resistant partial epilepsy (focal onset seizures) with or without secondary generalisation, that is where all other appropriate medicinal product combinations have proved inadequate or have not been tolerated.
https://www.ema.europa.eu/en/documents/product-information/kigabeq-epar-product-information_en.pdf
About infantile spasms
West syndrome, or infantile spasms, is an extremely serious epileptic encephalopathy in infants that combines epileptic spasms, psychomotor deterioration and a hypsarrhythmic type electroencephalogram. It is a rare disease, with an estimated incidence of 5 per 10,000 births. It can occur in an infant with previously normal development or with a pre-existing delay; in all cases, infantile spasms severely hamper the psychomotor development. Pharmacological treatment should be started quickly to allow the spasms to stop and to improve the prognosis.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRASEFFISEFSESW
(END) Dow Jones Newswires
July 21, 2021 04:00 ET (08:00 GMT)
1 Year Clinigen Chart |
1 Month Clinigen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions